newsfilter
← Latest News
GlobeNewswire·

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential